PURPOSE: To provide an exhaustive review of the neuropsychological examination as conducted in brain tumor clinical trials over the last 30 years and to provide objective ratings about the reliability and suitability of such tests in neurooncological research and clinical practice. METHODS: Methodologies and tools provided by the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) were exploited in order to assess the measurement properties of questionnaires and performance-based instruments used to evaluate cognitive functioning in brain tumor clinical trials from 1997 to 2017. RESULTS: Twenty-six brain tumor clinical trials were analyzed and an overall set of 10 neuropsychological tests was identified. A list of 24 studies concerning the reliability of such tests was analyzed. Reliability and level of evidence scores for each study and for each test were obtained. The results revealed relevant faults about the quality of measurements and the suitability of the neurocognitive assessment batteries most commonly used in brain tumor clinical trials. CONCLUSION: Our findings suggest that the cognitive assessment in brain tumor clinical trials should be implemented according to specific endpoints and should be addressed to investigate all the cognitive domains known to be affected by brain tumor and treatment.
PURPOSE: To provide an exhaustive review of the neuropsychological examination as conducted in brain tumor clinical trials over the last 30 years and to provide objective ratings about the reliability and suitability of such tests in neurooncological research and clinical practice. METHODS: Methodologies and tools provided by the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) were exploited in order to assess the measurement properties of questionnaires and performance-based instruments used to evaluate cognitive functioning in brain tumor clinical trials from 1997 to 2017. RESULTS: Twenty-six brain tumor clinical trials were analyzed and an overall set of 10 neuropsychological tests was identified. A list of 24 studies concerning the reliability of such tests was analyzed. Reliability and level of evidence scores for each study and for each test were obtained. The results revealed relevant faults about the quality of measurements and the suitability of the neurocognitive assessment batteries most commonly used in brain tumor clinical trials. CONCLUSION: Our findings suggest that the cognitive assessment in brain tumor clinical trials should be implemented according to specific endpoints and should be addressed to investigate all the cognitive domains known to be affected by brain tumor and treatment.
Authors: Ellen M P van Loon; Majanka H Heijenbrok-Kal; Wouter S van Loon; Martin J van den Bent; Arnaud J P E Vincent; Inge de Koning; Gerard M Ribbers Journal: J Rehabil Med Date: 2015-06 Impact factor: 2.912
Authors: Jennifer L Helfer; Patrick Y Wen; Jaishri Blakeley; Mark R Gilbert; Terri S Armstrong Journal: Neuro Oncol Date: 2016-03 Impact factor: 12.300
Authors: Derek R Johnson; Allison M Sawyer; Christina A Meyers; Brian Patrick O'Neill; Jeffrey S Wefel Journal: Neuro Oncol Date: 2012-04-16 Impact factor: 12.300
Authors: Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans Journal: Lancet Neurol Date: 2009-08-07 Impact factor: 44.182
Authors: Lidwine B Mokkink; Caroline B Terwee; Donald L Patrick; Jordi Alonso; Paul W Stratford; Dirk L Knol; Lex M Bouter; Henrica C W de Vet Journal: Qual Life Res Date: 2010-02-19 Impact factor: 4.147
Authors: Varna Jammula; James L Rogers; Elizabeth Vera; Alexa Christ; Heather E Leeper; Alvina Acquaye; Nicole Briceno; Anna Choi; Ewa Grajkowska; Jason E Levine; Matthew Lindsley; Jennifer Reyes; Kayla N Roche; Michael Timmer; Lisa Boris; Eric Burton; Nicole Lollo; Marissa Panzer; Matthew A Smith-Cohn; Marta Penas-Prado; Valentina Pillai; Brett J Theeler; Jing Wu; Mark R Gilbert; Terri S Armstrong Journal: Neurooncol Pract Date: 2022-05-14